不稳定心绞痛危险分层与冠脉病变、中医分型的关系
|
摘要
目的:探讨不稳定型心绞痛患者危险分层和冠状动脉病变、中医证型的关系,分析能否通过不稳定型心绞痛危险分层预测患者的冠状动脉病变程度,验证不同中医证型患者在危险分层中分布的差异,并进一步验证各证型组患者冠状动脉病变存在的客观差异,为确定中医的危险证型提供客观依据。方法:将145例不稳定心绞痛患者分为低危、中危、高危三组及心血瘀阻、痰浊壅塞、阴寒凝滞、心肾阴虚、气阴两虚、阳气虚衰六个证型组,并行冠状动脉造影检查,以冠状动脉病变Gensini法评分,对比分析危险分层、冠状动脉Gensini积分、病变支数、中医证型的关系。结果:高危、中危、低危组间患者冠状动脉Gensini积分、病变支数差异有统计学意义(P＜0.05),病变积分由高危组向低危组递减,低危组与高危组、中危组与高危组病变支数差异有统计学意义(P＜0.05),三组间冠状动脉病变部位差异无统计学意义(P＞0.05);各证型组间患者不稳定型心绞痛危险分层、冠状动脉病变Gensini积分的差异有统计学意义(P＜0.05)。痰浊壅塞型在高危组分布较多,并且其冠状动脉Gensini积分及三支病变比例最高,冠状动脉病变最为严重,初步判定痰浊壅塞型危险程度高于其他证型组;实证组与虚证组间冠状动脉病变积分,病变支数差异也有统计学意义(P＜0.05),以实证组冠状动脉病变Gensini积分相对较高(P＜0.05),而以虚症组冠状动脉病变支数相对较多(P＜0.05)。结论:不同危险分层患者间冠状动脉病变程度不同,由高危组向低危组递减;不同证型组患者在危险分层中分布不同、冠状动脉病变程度不同,痰浊壅塞型危险程度高于胸痹心痛其他证型组。
Objective: To study the relationship between clinical classification and angiography findings,syndrome tape of Traditional Chinese Medicine(TMC) in unstable angina pectoris. Method: 145 patients with unstable angina were divided into 3 groups according to the clinical classification standard and different TMC syndrome types, received coronary arteriography(CAG),The pathological changes among groups were compared and assessed by Gensini integral method. Results: The coronary lesion score in high risk group is higher than those two groups (P =0.000). It is shown that the unstable angina clinical classification has corellation with coronary lesion score, while There were differences in unstable angina clinical classification, Gensini score, number of coronary artery lesion between TMC syndrome groups (P<0.05). The coronary Gensini score in phlegm turbid syndrome group is higher than other groups and three artery lesion were the most in the group; Conclusions: The unstable angina clinical classification and syndrome tape of Traditional Chinese Medicine correlates with the coronary lesion degree.
Objective: To study the relationship between clinical classification and angiography findings,syndrome tape of Traditional Chinese Medicine(TMC) in unstable angina pectoris. Method: 145 patients with unstable angina were divided into 3 groups according to the clinical classification standard and different TMC syndrome types, received coronary arteriography(CAG),The pathological changes among groups were compared and assessed by Gensini integral method. Results: The coronary lesion score in high risk group is higher than those two groups (P =0.000). It is shown that the unstable angina clinical classification has corellation with coronary lesion score, while There were differences in unstable angina clinical classification, Gensini score, number of coronary artery lesion between TMC syndrome groups (P<0.05). The coronary Gensini score in phlegm turbid syndrome group is higher than other groups and three artery lesion were the most in the group; Conclusions: The unstable angina clinical classification and syndrome tape of Traditional Chinese Medicine correlates with the coronary lesion degree.
引文
铩颷1]SamuelZ.Goldhaber.肺栓塞.见:[美]Braunwald.[译]陈灏珠.心脏病学[M].第5版.北京:人民教育出版社,1999:1433
[2]Sun RJ,Muller S,Wang X,et al.Regulation of von Willebrand factorof human endothelial cells exposed to laminar flows:an in vitro study[J].Clin Hemorheol Microcirc,2000,23(Ⅰ):1-11
[3]胡大一,庞文跃.心血管病诊疗指南解读[M].北京:人民出版社,2004:365
[4]Koukkunen H,K Pyorala and O H M.Low-risk patients with chest painand without evidence of myocardial infarction may be safely dischargedfrom emergency department.Eur Heart J,2004,25(4):329-334
[5]Sabatine MS,McCabe CH,Morrow DA,et al.Identification of patientsat high risk for death and cardiac ischemic events after hospitaldischarge.Am Heart J,2002,143(6):966-970
[6]Wallentin L,Lagerqvist B,Husted S for the FRISC ⅡInvestigators:outcome at 1 year after an invasive compared to a non-invasive strategyin unstable coronary artery disease:the FRISC Ⅱ invasive randomisedtrial.Lancet,2000,356:9-16
[7]王兴德,李淮,何梅先.高危不稳定型心绞痛患者临床和冠状脉造影特点,中国心血管病研究杂志[J].2003,18(1):33
[8]孙尧,不稳定型心绞痛危险分层和冠状动脉造影的关系中国心血管病研究杂志[J].2003,21,(4):21
[9]李峰,李秀云,王长海.冠心病冠状动脉病变与中医证型关系分析[J].陕西中医,1996,17(9):393
[10]李佃贵,李俊峡,李振彬,等.冠心病患者病变程度与中医证型的关系[J].中国中医药信息志,2001,8(12):57-58
[11]张敏州,丁邦晗,张维东,等.375例胸痹心痛患者冠状动脉造影结果与中医证型的对比研究[J].中国中西医结合急救,2004,11(2):333
[12]黄腾蛟,嵇美霞,史大卓,111例冠心病中医辨证分型研究,现代中西医结合杂志[J].2004,13(2):172
[13]尹克春,周文斌,陈力,等,89例冠状动脉造影与冠心病中医证型相关性研究[J].中医研究,2005,18(4):25
[14]张广增,415例胸痹心痛患者冠状动脉造影结果分析[J],四川中医.2006, 24(3):25
铩颷15]中华医学会心血管病会.中华心血管病杂志编辑委员会.不稳定性心绞痛诊断和治疗的建议[J].中华心血管病杂志.2000,28,409-412
[16]郑筱萸.中药新药临床研究指导原则,北京:中国医药科技出版社,2002年,第1版:68-73
[17]Libby P,Molecular basis of the acute coronary syndromes.Circulation,1995;91:2841-50
[18]Falk E,Shah PK,Fuster V coronary plaque disruption.Circulation,1995;92:657-71
[19]Filippo C,Luigi MB,Antonino B,et al.Roie of inflammation in thepatbogenesis of unstable coronary artery disease,Am J Cardiol,1997,80(5A):10E-16E
[20]Hoffmeister H M,Ehlers R,ButterE et al Comparison of C-reactiveprotein and terminal complement complex in patients with unstableangina pectoris versus stable angina pectoris[J].Am J Cardiol,2002,89909-912
[21]IftikharJK,William DE,Robert SS.Vulnerable plaque:pathobiology andclinical implications.Ann Intern Med,1998;129:1050-60
[22]Falk E Why do plaque rupture? Circulation,1992,86.Ⅲ30-Ⅲ42
[23]Davies MJ,Richardson PD,Woolf N,et al.Risk of thrombosis in humanatherosclerotic plaques role of extracellular lipid,macrophage andsmooth muscle cell component.Br Heart J,1993;69:377-381
[24]Libby P,Geng YJ,Aikawa M,et al.Macrophage and atherosclerotic plaquestability.Curr Opin Lipidol,1996,7:330-335
[25]FusterV.Thepathogenes is of coronaryarterydiseaseand the acutecoronary syndrorrns N Engl[J]Med,1992 326:242
[26]Retterstol L,Eikvar L,Bohn M,et al.Creactive protein predicts deathin patients with previous myocardial infarction a 10 year follow-upstudy[J]Athetnsclerosis,2002,160(2):433-440
[27]Falk E,et al.Coronary plaque disruption.Circulation,1995,92:657
[28]刘慧,基质金属蛋白酶在血管成形术后再狭窄中的研究[J].实用诊断与治疗杂志,2005,19(6):424
[29]SCHUMACHERA,SELJEFLOTI,SOMMERVOLLL,et al.Increased Levels ofendothelial haemost at ic markers in patient swith coronary heart disease[J].ThrombRes,2002,105:25-31
铩颷30]马首雁,李秀荣.多层螺旋CT冠状动脉成像在不稳定心绞痛中的应用价值[J].吉林医学,2006,3(27):318
[31]Schroeder S,Kopp AE,Baumbach A,et al.Noninvasive detection AndevalUAPtion of atheroslerotic coronary plaques with multislicecomputed tomography[J].JAmColl Cardio,2001,37(5):1430
[32]Achenbach S,GieslerT,RopesD,et al.Detection of coronary Arterystenosis by contrast-enhanced,retrospecticely electrocardio-graphically-gated,multislice spiral computed tomography[J].Circula-tion,2001,103(20):2535
[33]Brignori C,Anzuini A.Airnldi F.et al.Intravascular altrsoundcriterria for the assessment of the functional significane ofintermediate coronary artery stenoses and comparison with fractionalflow reserve[J].AM,J Cardiol,2001,87(2):136
[34]鲁静朝,崔炜.易破裂斑块的血管内检查[J].国外医学心血管疾病分册,2005,32(1):28
[35]马淑梅,李晓东,孙亚清,等.冠状动脉血管内视镜对无症状性斑块破裂的观察及其与冠心病危险囚了关系的探讨[J].中华心血管病杂志,2002,30(2):90
[36]杨志健主编.冠心病介入诊疗[M]南京:江苏科学技术出版社,2000:127
[37]Grube E,Gerekens U,Buellesfeld L,et al.Imagesin Cardiovascularmedicine.Intracoronary imaging with optical Coherence tomography.Anew high-resolution technology striking visUAPlization in thecoronary artery[J].Circulation,2002,106(18):2409
[38]Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA guideline updatefor the management of patients with unstable angina and non-ST-segmentmyocardial infarction:a report of the American College ofCardiology/American Heart Association Task Force on PracticeGuidelines(Committee on the Management of Patients with UnstableAngina).J Am Coll Cardiol,2002,40(7):1366-1374
[39]Koukkunen H,K Pyorala and O H M.Low-risk patients with chest painand without evidence of myocardial infarction may be safely dischargedfrom emergency department.Eur Heart J,2004,25(4):329-334
[40]Natarajan M.Unstable angina.Clin Evi,2002,7:214-226
[41]Bertrand ME,Simoons ML,Fox KA,et al.Management of acute coronary syndromes in patients presenting without persistent ST segment elevation: the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J, 2002,23:1809-1840
[42] Antman EM, Tanasijevie MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med, 1996, 335:1342-1349
[43] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiao, 2001, 38:478-485
[44] Tanasijevie MJ, Cannon CP, Antman EM. The role of troponin I(cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol, 1999, 22:13-16
[45] Lindahl B, Venge P, Wallentin L. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol, 1997,29:43-48
[46] Heeschen C, Hamm CW, Goldmann B, et al. Platelet Receptor Inhibition in Ischemic Syndromes Management (PRISM) Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet, 1999,354:1757-1762
[47] Collinson J, Flather, Fox KAA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST segment elevation: Prospective Registry of Acute Ischemic Syndromes in the UK (PRAIS-UK). Eur Heart J, 2000, 21:1450-1457
[48] Rebuzzi AG, QUAPranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol, 1998, 82:715-719
[49] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284:835-842
[50] Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol, 1995, Jun;25(7 Suppl):10S-17S
[51] Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarction myocardium early II trial substudy. Circulation, 2000,102:2031-2037
[52] The PURSUIT Trial. Investigators Inhibition of platelet glycoprotein II b/III a with eptifibatide in patients with acute coronary syndromes N Engl J Med, 1998, Aug 13,339:436-443
[53] David A, Morrow MD, Elliott M, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation, 2000, 102:2031
[54] Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet, 2002,360(9335): 743-751
[55] Ohman EM, Granger CB, Hamington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA, 2000, 284:876-878
[56] Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICUPE study. Lancet, 2001,358:527-533
[57] Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA, 2003,289(3):331-342
[58] Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345:494-502
[59] Peterson ED, Pollack CV Jr, Roe MT, et al. Early use of glycoprotein II b/III a inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol, 2003, 42(1):45-53
铩颷60]McKay R G."Ischemia-guided" versus "early invasive" strategiesin the management of acute coronary syndrome/non-ST-segment elevationmyocardial infarction:the interventionalist's perspective.J Am CollCardiol,2003,41(4 Suppl S):96S-102S
[61]Aronow HD,Topol EJ,Roe MT,et al.Effect of lipid-lowering therapyon early mortality after acute coronary syndromes:an observationalstudy.Lancet,2001,357(9262):1063-1068
[62]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatinon early recurrent ischemic events in acute coronary syndromes:TheMIRACL study:a randomized controlled trial.JAMA,2001,285(13):1711-1718
[63]Pasternad RC,Smith SC Jr,Bairey-Merz CN,et al.ACC/AHA/NHLBIClinical advisory on the use and safety of statins.J Am Coll Cardiol,2002,40(3):567-572
[64]刘德桓,许真真,郭伟聪.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995;36(10):617
[65]何熹延,丁惠玲,娄彬.21例自发性及变异性心绞痛的中医证候特点分析[J].中国中西医结合杂志,1992;12(1):14
[66]吴启富,顾关良.冠心病变异性心绞痛中医证型研究[J].云南中医中药杂志,1995:16(2):14
[67]邓宝澄.不稳定性心绞痛中医治疗概况[J].右江民族医学院学报,2002;24(5):765
[68]吴以岭.从络病学说论治冠心病心绞痛[J].中国中医基础医学杂志,2001;7(4):71
[69]檀金川,谢惠芬,齐丽娟.温散寒凝熄风通络法治疗不稳定心绞痛34例[J].陕西中医,1995;16(9):388
[70]李十红.李祥国治疗冠状动脉痉挛心绞痛的经验[J].辽宁中医杂志,1997;24(2):55
[71]王显刚.益气活血解毒法对不稳定性心绞痛患者血管内皮保护与抑制血小板活化作用[J].山东生物医学工程,2002,12(1):24-26
[72]邓宝澄.自拟冠心通汤防治不稳定性心绞痛35例[J].辽宁中医杂志,2002.29(2):90
[73]陈鹏.心痛安颗粒对不稳定性心绞痛患者血浆内皮素(ET)和一氧化氮(NO)的影响[J].四川中医,2002,20:21
[1] Shesser R, Smith M. The chest pain emergency department and the out-patient chest pain evalUAPtion center: revolution or evolution? Ann Emerg Med, 1994, 23:311-329
[2] Sabatine MS, McCabe CH, Morrow DA, et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J, 2002, 143(6) :966-970
[3] Koukkunen H, K Pyorala and 0 H M. Low-risk patients with chest pain and without evidence of myocardial infarction may be safely discharged from emergency department. Eur Heart J, 2004, 25(4):329-334
[4] Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol, 2002, 40(7):1366-1374
[5] Koukkunen H, K Pyorala and O H M. Low-risk patients with chest pain and without evidence of myocardial infarction may be safely discharged from emergency department. Eur Heart J, 2004, 25(4):329-334
[6] Natarajan M. Unstable angina. Clin Evi, 2002,7:214-226
[7] Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation: the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J, 2002, 23:1809-1840
[8] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta- analysis. J Am Coll Cardiao, 2001, 38:478-485
[9] Tanasijevie MJ, Cannon CP, Antman EM. The role of troponin I(cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol,1999, 22:13-16
[10] Lindahl B, Venge P, Wallentin L. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrorabotic protection. J Am Coll Cardiol, 1997, 29:43-48
[11] Heeschen C, Haram CW, Goldmann B, et al. Platelet Receptor Inhibition in Ischemic Syndromes Management (PRISM) Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet,1999, 354:1757-1762
[12] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiao, 2001, 38:478-485
[13] Rebuzzi AG, QUAPranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol, 1998, 82:715-719
[14] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284:835-842
[15] Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol, 1995, Jun;25(7 Suppl):10S-17S
[16] Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarction myocardium early II trial substudy. Circulation, 2000,102:2031-2037
[17] The PURSUIT Trial. Investigators Inhibition of platelet glycoprotein II b/III a with eptifibatide in patients with acute coronary syndromes N Engl J Med, 1998, Aug 13,339:436-443
[18] David A, Morrow MD, Elliott M, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation, 2000,102:2031
[19] Ohman EM, Granger CB, Hamington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA, 2000, 284:876-878
铩颷20]Wallentin L,Lagerqvist B,Husted S for the FRISC ⅡInvestigators:outcome at 1 year after an invasive compared to a non-invasive strategyin unstable coronary artery disease:the FRISC Ⅱ invasive randomisedtrial.Lancet,2000,356:9-16
[21]Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment withclopidogrel and aspirin followed by long-term therapy in patientsundergoing percutaneous coronary intervention:the PCICUPE study.Lancet,2001,358:527-533
[22]Wong GC,Giugliano RP,Antman EM.Use of low-molecular-weight heparinsin the management of acute coronary artery syndromes and percutaneouscoronary intervention.JAMA,2003.289(3):331-342
[23]Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in additionto aspirin in patients with acute coronary syndromes without ST-segmentelevation.N Engl J Med,2001,345:494-502
[24]Peterson ED,Pollack CV Jr,Roe MT,et al.Early use of glycoproteinⅡb/Ⅲ a inhibitors in non-ST-elevation acute myocardial infarction:observations from the National Registry of Myocardial Infarction 4.J Am Coll Cardiol,2003,42(1):45-53
[25]McKay R G."Ischemia-guided" versus "early invasive" strategiesin the management of acute coronary syndrome/non-ST-segment elevationmyocardial infarction:the interventionalist's perspective.J Am CollCardiol,2003,41(4 Suppl S):96S-102S
[26]黄文增.当归注射液对高血压病患者血浆血栓素A2及前列素的影响[J].中国中西医结合杂志,1999,19(3):143
[27]魏晓东,李莉.复方丹参对冠心病患者红细胞膜磷脂成分的影响[J].中国中西医结合杂志,1997,17(6):336
[28]杨雪英.复方丹参注射液对冠心病合并充血性心力衰竭患者钙素基因相关肽和内皮素的影响[J].中国中西医结合杂志,2001,21(2):137
[29]郭杜鹏,张言镇Tc-MIBL心肌显像评价参麦注射液对A2MI溶栓再灌注心肌的保护作用[J].中国中西医结合杂志,2001,21(2):108
[30]吴刚.黄芪丹参液治疗急性心梗疗效及分析[J].临床心血管病杂志,2001,17(2):91
[31]江头亨.人参养荣汤的药理学基础研究[J].国外医学中医中药分册,2001,23:2
铩颷32]陈红斌 1葛根素对冠心病患者纤溶功能及过氧化脂质的影响[J].中国中西医结合杂志,1999,19(11):649
[33]苏建文,吴伟庚.四逆汤对PICA血液流变性的改变作用[J].中国中西医结合杂志,1997,17(1):34
[34]吴伟庚.四逆汤防治PTCD术的再灌注损伤的作用机制及中医辨证分型的临床研究[J].中国中西医结合杂志,1999,19(1):23
[2]Sun RJ,Muller S,Wang X,et al.Regulation of von Willebrand factorof human endothelial cells exposed to laminar flows:an in vitro study[J].Clin Hemorheol Microcirc,2000,23(Ⅰ):1-11
[3]胡大一,庞文跃.心血管病诊疗指南解读[M].北京:人民出版社,2004:365
[4]Koukkunen H,K Pyorala and O H M.Low-risk patients with chest painand without evidence of myocardial infarction may be safely dischargedfrom emergency department.Eur Heart J,2004,25(4):329-334
[5]Sabatine MS,McCabe CH,Morrow DA,et al.Identification of patientsat high risk for death and cardiac ischemic events after hospitaldischarge.Am Heart J,2002,143(6):966-970
[6]Wallentin L,Lagerqvist B,Husted S for the FRISC ⅡInvestigators:outcome at 1 year after an invasive compared to a non-invasive strategyin unstable coronary artery disease:the FRISC Ⅱ invasive randomisedtrial.Lancet,2000,356:9-16
[7]王兴德,李淮,何梅先.高危不稳定型心绞痛患者临床和冠状脉造影特点,中国心血管病研究杂志[J].2003,18(1):33
[8]孙尧,不稳定型心绞痛危险分层和冠状动脉造影的关系中国心血管病研究杂志[J].2003,21,(4):21
[9]李峰,李秀云,王长海.冠心病冠状动脉病变与中医证型关系分析[J].陕西中医,1996,17(9):393
[10]李佃贵,李俊峡,李振彬,等.冠心病患者病变程度与中医证型的关系[J].中国中医药信息志,2001,8(12):57-58
[11]张敏州,丁邦晗,张维东,等.375例胸痹心痛患者冠状动脉造影结果与中医证型的对比研究[J].中国中西医结合急救,2004,11(2):333
[12]黄腾蛟,嵇美霞,史大卓,111例冠心病中医辨证分型研究,现代中西医结合杂志[J].2004,13(2):172
[13]尹克春,周文斌,陈力,等,89例冠状动脉造影与冠心病中医证型相关性研究[J].中医研究,2005,18(4):25
[14]张广增,415例胸痹心痛患者冠状动脉造影结果分析[J],四川中医.2006, 24(3):25
铩颷15]中华医学会心血管病会.中华心血管病杂志编辑委员会.不稳定性心绞痛诊断和治疗的建议[J].中华心血管病杂志.2000,28,409-412
[16]郑筱萸.中药新药临床研究指导原则,北京:中国医药科技出版社,2002年,第1版:68-73
[17]Libby P,Molecular basis of the acute coronary syndromes.Circulation,1995;91:2841-50
[18]Falk E,Shah PK,Fuster V coronary plaque disruption.Circulation,1995;92:657-71
[19]Filippo C,Luigi MB,Antonino B,et al.Roie of inflammation in thepatbogenesis of unstable coronary artery disease,Am J Cardiol,1997,80(5A):10E-16E
[20]Hoffmeister H M,Ehlers R,ButterE et al Comparison of C-reactiveprotein and terminal complement complex in patients with unstableangina pectoris versus stable angina pectoris[J].Am J Cardiol,2002,89909-912
[21]IftikharJK,William DE,Robert SS.Vulnerable plaque:pathobiology andclinical implications.Ann Intern Med,1998;129:1050-60
[22]Falk E Why do plaque rupture? Circulation,1992,86.Ⅲ30-Ⅲ42
[23]Davies MJ,Richardson PD,Woolf N,et al.Risk of thrombosis in humanatherosclerotic plaques role of extracellular lipid,macrophage andsmooth muscle cell component.Br Heart J,1993;69:377-381
[24]Libby P,Geng YJ,Aikawa M,et al.Macrophage and atherosclerotic plaquestability.Curr Opin Lipidol,1996,7:330-335
[25]FusterV.Thepathogenes is of coronaryarterydiseaseand the acutecoronary syndrorrns N Engl[J]Med,1992 326:242
[26]Retterstol L,Eikvar L,Bohn M,et al.Creactive protein predicts deathin patients with previous myocardial infarction a 10 year follow-upstudy[J]Athetnsclerosis,2002,160(2):433-440
[27]Falk E,et al.Coronary plaque disruption.Circulation,1995,92:657
[28]刘慧,基质金属蛋白酶在血管成形术后再狭窄中的研究[J].实用诊断与治疗杂志,2005,19(6):424
[29]SCHUMACHERA,SELJEFLOTI,SOMMERVOLLL,et al.Increased Levels ofendothelial haemost at ic markers in patient swith coronary heart disease[J].ThrombRes,2002,105:25-31
铩颷30]马首雁,李秀荣.多层螺旋CT冠状动脉成像在不稳定心绞痛中的应用价值[J].吉林医学,2006,3(27):318
[31]Schroeder S,Kopp AE,Baumbach A,et al.Noninvasive detection AndevalUAPtion of atheroslerotic coronary plaques with multislicecomputed tomography[J].JAmColl Cardio,2001,37(5):1430
[32]Achenbach S,GieslerT,RopesD,et al.Detection of coronary Arterystenosis by contrast-enhanced,retrospecticely electrocardio-graphically-gated,multislice spiral computed tomography[J].Circula-tion,2001,103(20):2535
[33]Brignori C,Anzuini A.Airnldi F.et al.Intravascular altrsoundcriterria for the assessment of the functional significane ofintermediate coronary artery stenoses and comparison with fractionalflow reserve[J].AM,J Cardiol,2001,87(2):136
[34]鲁静朝,崔炜.易破裂斑块的血管内检查[J].国外医学心血管疾病分册,2005,32(1):28
[35]马淑梅,李晓东,孙亚清,等.冠状动脉血管内视镜对无症状性斑块破裂的观察及其与冠心病危险囚了关系的探讨[J].中华心血管病杂志,2002,30(2):90
[36]杨志健主编.冠心病介入诊疗[M]南京:江苏科学技术出版社,2000:127
[37]Grube E,Gerekens U,Buellesfeld L,et al.Imagesin Cardiovascularmedicine.Intracoronary imaging with optical Coherence tomography.Anew high-resolution technology striking visUAPlization in thecoronary artery[J].Circulation,2002,106(18):2409
[38]Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA guideline updatefor the management of patients with unstable angina and non-ST-segmentmyocardial infarction:a report of the American College ofCardiology/American Heart Association Task Force on PracticeGuidelines(Committee on the Management of Patients with UnstableAngina).J Am Coll Cardiol,2002,40(7):1366-1374
[39]Koukkunen H,K Pyorala and O H M.Low-risk patients with chest painand without evidence of myocardial infarction may be safely dischargedfrom emergency department.Eur Heart J,2004,25(4):329-334
[40]Natarajan M.Unstable angina.Clin Evi,2002,7:214-226
[41]Bertrand ME,Simoons ML,Fox KA,et al.Management of acute coronary syndromes in patients presenting without persistent ST segment elevation: the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J, 2002,23:1809-1840
[42] Antman EM, Tanasijevie MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med, 1996, 335:1342-1349
[43] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiao, 2001, 38:478-485
[44] Tanasijevie MJ, Cannon CP, Antman EM. The role of troponin I(cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol, 1999, 22:13-16
[45] Lindahl B, Venge P, Wallentin L. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol, 1997,29:43-48
[46] Heeschen C, Hamm CW, Goldmann B, et al. Platelet Receptor Inhibition in Ischemic Syndromes Management (PRISM) Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet, 1999,354:1757-1762
[47] Collinson J, Flather, Fox KAA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST segment elevation: Prospective Registry of Acute Ischemic Syndromes in the UK (PRAIS-UK). Eur Heart J, 2000, 21:1450-1457
[48] Rebuzzi AG, QUAPranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol, 1998, 82:715-719
[49] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284:835-842
[50] Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol, 1995, Jun;25(7 Suppl):10S-17S
[51] Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarction myocardium early II trial substudy. Circulation, 2000,102:2031-2037
[52] The PURSUIT Trial. Investigators Inhibition of platelet glycoprotein II b/III a with eptifibatide in patients with acute coronary syndromes N Engl J Med, 1998, Aug 13,339:436-443
[53] David A, Morrow MD, Elliott M, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation, 2000, 102:2031
[54] Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet, 2002,360(9335): 743-751
[55] Ohman EM, Granger CB, Hamington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA, 2000, 284:876-878
[56] Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICUPE study. Lancet, 2001,358:527-533
[57] Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA, 2003,289(3):331-342
[58] Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345:494-502
[59] Peterson ED, Pollack CV Jr, Roe MT, et al. Early use of glycoprotein II b/III a inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol, 2003, 42(1):45-53
铩颷60]McKay R G."Ischemia-guided" versus "early invasive" strategiesin the management of acute coronary syndrome/non-ST-segment elevationmyocardial infarction:the interventionalist's perspective.J Am CollCardiol,2003,41(4 Suppl S):96S-102S
[61]Aronow HD,Topol EJ,Roe MT,et al.Effect of lipid-lowering therapyon early mortality after acute coronary syndromes:an observationalstudy.Lancet,2001,357(9262):1063-1068
[62]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatinon early recurrent ischemic events in acute coronary syndromes:TheMIRACL study:a randomized controlled trial.JAMA,2001,285(13):1711-1718
[63]Pasternad RC,Smith SC Jr,Bairey-Merz CN,et al.ACC/AHA/NHLBIClinical advisory on the use and safety of statins.J Am Coll Cardiol,2002,40(3):567-572
[64]刘德桓,许真真,郭伟聪.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995;36(10):617
[65]何熹延,丁惠玲,娄彬.21例自发性及变异性心绞痛的中医证候特点分析[J].中国中西医结合杂志,1992;12(1):14
[66]吴启富,顾关良.冠心病变异性心绞痛中医证型研究[J].云南中医中药杂志,1995:16(2):14
[67]邓宝澄.不稳定性心绞痛中医治疗概况[J].右江民族医学院学报,2002;24(5):765
[68]吴以岭.从络病学说论治冠心病心绞痛[J].中国中医基础医学杂志,2001;7(4):71
[69]檀金川,谢惠芬,齐丽娟.温散寒凝熄风通络法治疗不稳定心绞痛34例[J].陕西中医,1995;16(9):388
[70]李十红.李祥国治疗冠状动脉痉挛心绞痛的经验[J].辽宁中医杂志,1997;24(2):55
[71]王显刚.益气活血解毒法对不稳定性心绞痛患者血管内皮保护与抑制血小板活化作用[J].山东生物医学工程,2002,12(1):24-26
[72]邓宝澄.自拟冠心通汤防治不稳定性心绞痛35例[J].辽宁中医杂志,2002.29(2):90
[73]陈鹏.心痛安颗粒对不稳定性心绞痛患者血浆内皮素(ET)和一氧化氮(NO)的影响[J].四川中医,2002,20:21
[1] Shesser R, Smith M. The chest pain emergency department and the out-patient chest pain evalUAPtion center: revolution or evolution? Ann Emerg Med, 1994, 23:311-329
[2] Sabatine MS, McCabe CH, Morrow DA, et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J, 2002, 143(6) :966-970
[3] Koukkunen H, K Pyorala and 0 H M. Low-risk patients with chest pain and without evidence of myocardial infarction may be safely discharged from emergency department. Eur Heart J, 2004, 25(4):329-334
[4] Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol, 2002, 40(7):1366-1374
[5] Koukkunen H, K Pyorala and O H M. Low-risk patients with chest pain and without evidence of myocardial infarction may be safely discharged from emergency department. Eur Heart J, 2004, 25(4):329-334
[6] Natarajan M. Unstable angina. Clin Evi, 2002,7:214-226
[7] Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation: the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J, 2002, 23:1809-1840
[8] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta- analysis. J Am Coll Cardiao, 2001, 38:478-485
[9] Tanasijevie MJ, Cannon CP, Antman EM. The role of troponin I(cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol,1999, 22:13-16
[10] Lindahl B, Venge P, Wallentin L. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrorabotic protection. J Am Coll Cardiol, 1997, 29:43-48
[11] Heeschen C, Haram CW, Goldmann B, et al. Platelet Receptor Inhibition in Ischemic Syndromes Management (PRISM) Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet,1999, 354:1757-1762
[12] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiao, 2001, 38:478-485
[13] Rebuzzi AG, QUAPranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol, 1998, 82:715-719
[14] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284:835-842
[15] Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol, 1995, Jun;25(7 Suppl):10S-17S
[16] Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarction myocardium early II trial substudy. Circulation, 2000,102:2031-2037
[17] The PURSUIT Trial. Investigators Inhibition of platelet glycoprotein II b/III a with eptifibatide in patients with acute coronary syndromes N Engl J Med, 1998, Aug 13,339:436-443
[18] David A, Morrow MD, Elliott M, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation, 2000,102:2031
[19] Ohman EM, Granger CB, Hamington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA, 2000, 284:876-878
铩颷20]Wallentin L,Lagerqvist B,Husted S for the FRISC ⅡInvestigators:outcome at 1 year after an invasive compared to a non-invasive strategyin unstable coronary artery disease:the FRISC Ⅱ invasive randomisedtrial.Lancet,2000,356:9-16
[21]Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment withclopidogrel and aspirin followed by long-term therapy in patientsundergoing percutaneous coronary intervention:the PCICUPE study.Lancet,2001,358:527-533
[22]Wong GC,Giugliano RP,Antman EM.Use of low-molecular-weight heparinsin the management of acute coronary artery syndromes and percutaneouscoronary intervention.JAMA,2003.289(3):331-342
[23]Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in additionto aspirin in patients with acute coronary syndromes without ST-segmentelevation.N Engl J Med,2001,345:494-502
[24]Peterson ED,Pollack CV Jr,Roe MT,et al.Early use of glycoproteinⅡb/Ⅲ a inhibitors in non-ST-elevation acute myocardial infarction:observations from the National Registry of Myocardial Infarction 4.J Am Coll Cardiol,2003,42(1):45-53
[25]McKay R G."Ischemia-guided" versus "early invasive" strategiesin the management of acute coronary syndrome/non-ST-segment elevationmyocardial infarction:the interventionalist's perspective.J Am CollCardiol,2003,41(4 Suppl S):96S-102S
[26]黄文增.当归注射液对高血压病患者血浆血栓素A2及前列素的影响[J].中国中西医结合杂志,1999,19(3):143
[27]魏晓东,李莉.复方丹参对冠心病患者红细胞膜磷脂成分的影响[J].中国中西医结合杂志,1997,17(6):336
[28]杨雪英.复方丹参注射液对冠心病合并充血性心力衰竭患者钙素基因相关肽和内皮素的影响[J].中国中西医结合杂志,2001,21(2):137
[29]郭杜鹏,张言镇Tc-MIBL心肌显像评价参麦注射液对A2MI溶栓再灌注心肌的保护作用[J].中国中西医结合杂志,2001,21(2):108
[30]吴刚.黄芪丹参液治疗急性心梗疗效及分析[J].临床心血管病杂志,2001,17(2):91
[31]江头亨.人参养荣汤的药理学基础研究[J].国外医学中医中药分册,2001,23:2
铩颷32]陈红斌 1葛根素对冠心病患者纤溶功能及过氧化脂质的影响[J].中国中西医结合杂志,1999,19(11):649
[33]苏建文,吴伟庚.四逆汤对PICA血液流变性的改变作用[J].中国中西医结合杂志,1997,17(1):34
[34]吴伟庚.四逆汤防治PTCD术的再灌注损伤的作用机制及中医辨证分型的临床研究[J].中国中西医结合杂志,1999,19(1):23
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |